Connect Biopharma Holdings (CNTB) Free Cash Flow (2024 - 2026)

Connect Biopharma Holdings (CNTB) has reported Free Cash Flow for 3 consecutive years, with -$16.0 million the latest figure, recorded in Q1 2026.

• Quarterly Free Cash Flow fell 59.39% year-over-year to -$16.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$57.8 million (down 70.88% YoY) and the FY2025 annual result came in at -$51.8 million, down 112.67% from the prior year.
• Free Cash Flow slipped to -$16.0 million in Q1 2026 per CNTB's latest filing, from -$11.4 million in the prior quarter.
• Over the last five years, Free Cash Flow for CNTB reached as high as -$592000.0 in Q1 2024 and fell as low as -$17.4 million in Q3 2025.
• A 3-year average of -$10.2 million and a median of -$11.4 million in 2025 frame the typical range for Free Cash Flow.
• The largest YoY upside for Free Cash Flow was 32.58% in 2025 against a maximum downside of 1595.95% in 2025.
• Year by year, Free Cash Flow stood at -$2.6 million in 2024, then plunged by 334.54% to -$11.4 million in 2025, then plunged by 39.92% to -$16.0 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$16.0 million, -$11.4 million, and -$17.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.